ClinicalTrials.gg
CompletedNCT05083468Updated Nov 29, 2024

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

A Phase 1 interventional study of SR750 tablet and matching placebo in Healthy Volunteers, sponsored by Shanghai SIMR Biotechnology Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Shanghai SIMR Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is to evaluate the safety, tolerability, and PK of SR750 in healthy volunteers.

Read the detailed description

This study is a randomized, double-blinded, placebo-controlled, 2-part Phase I study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of SR750 in healthy volunteers. This study includes 2 parts:

Part A is a double-blind, randomized, placebo-controlled, single-dose escalation study of SR750 in healthy volunteers.

Part B is a double-blind, randomized, placebo-controlled, repeated-dose escalation study of SR750 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai SIMR Biotechnology Co., Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteers will be included in the study if they satisfy all the following criteria:

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. (BMI) ≥ 18.0 and ≤ 32.0 kg/m2, with a body weight ≥ 50 kg for males or ≥ 45 kg for females at screening.
  4. Use of tobacco or nicotine-containing products:

    1. Have less than 10 tobacco or nicotine-containing products (including tobacco, e-cigarettes) per week in the last 3 months prior to dosing; abstain from smoking from 7 days prior to dosing until the final follow-up visit;
    2. Have not used any marijuana in the 3 months prior to screening until the end of study.
  5. Medically healthy without abnormalities at the screening visit, at check-in on Day -1, and pre-dose on Day 1, including:

    1. Physical examination without any clinically relevant findings;
    2. Systolic blood pressure in the range of 90 to 140 mmHg (inclusive) and diastolic blood pressure in the range of 40 to 90 mmHg (inclusive) after 5 minutes in supine position;
    3. Pulse rate in the range of 60 to 100 bpm, inclusive (40-60 bpm [inclusive] may be considered acceptable for athletes or volunteers without clinical significance at the discretion of the PI or designee) after 5 minutes rest in supine position;
    4. Body temperature (tympanic), between 35.5°C and 37.5°C (inclusive);
    5. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests as judged by the Investigator.
  6. Conventional 12-lead (ECG) recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at the screening visit, on Day 1 and pre-dose on Day 1) consistent with normal cardiac conduction and function, including:

    1. T interval corrected using the Fridericia method () ≤ 450 msec for males, and ≤ 470 msec for females;
    2. QRS (wave group of Q, R and S in ECG) duration of ≤ 120 msec;
    3. Electrocardiogram morphology consistent with healthy cardiac ventricular conduction and normal rhythm, and with measurement of the QT interval;
    4. No family history of short or long QT syndrome, or sudden cardiac death;
    5. No history of torsade de pointes or a known arrhythmia.
  7. Healthy female volunteers must:

    a) Of non-, defined as: i. Pre-menopausal females with a documented tubal ligation, tubal occlusion procedure followed by a hysterosalpingogram that confirmed bilateral tubal occlusion, bilateral salpingectomy, hysterectomy, bilateral oophorectomy, or other documented medical conditions which cause infertility and are considered to be of non-childbearing potential; Note: "documented" refers to the outcome of the Investigator's/designee's review of the healthy volunteer's medical history for study eligibility, as obtained via a verbal interview with the healthy volunteer or from the healthy volunteer's medical records).

    ii. , defined as a minimum of 12 months of spontaneous amenorrhea (in questionable cases a blood sample with follicle stimulating hormone [FSH] >40 Million International Units (mIU)/mL is confirmatory).

    b) If of childbearing potential, must have a negative pregnancy test at the screening visit (blood test) and before the first study drug administration (Day -1 urine test). They must agree not to attempt to become pregnant, must not be breastfeeding, must not donate ova from signing the consent form until at least 30 days after the last does of study drug, and must agree to: i. Use 2 forms of highly effective method at least 2 weeks prior to screening, between signing consent, during the study, and at least 30 days after the last dose of study therapy, OR ii. Use at least one highly effective contraceptive method, plus an additional barrier-method of contraception at least 2 weeks prior to screening, between signing the consent, during the study, and at least 30 days after the last dose of study drug. Acceptable barrier methods include: female diaphragm condom usage for male partner, OR iii. True abstinence condition at least 2 weeks prior to screening, between signing consent, during the study, and at least 30 days after the last dose of study therapy.

    c) Women of childbearing potential (WOCBP) with solely same sex partners (abstinence from penile-vaginal intercourse) are eligible when this is their preferred and usual lifestyle.

  8. Male healthy volunteers, if not surgically sterilised (defined as performed at least 3 months prior to the first dose which could be confirmed by the documentation or verbal interview), must be willing not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must be willing to use a condom in addition to having the female partner use a highly effective contraceptive method from signing the consent form until at least 90 days after the last dose of study drug. If engaging in sexual intercourse with a pregnant partner, must be willing to use a barrier-method of contraception. Male healthy volunteers with same-sex partner (abstinence from penile-vaginal intercourse) and male healthy volunteers who are true abstinence are eligible when this is their preferred and usual lifestyle.
  9. Male participants must be willing to use a condom if engaging in sexual intercourse with a same sex partner from signing the consent form until study exit.
  10. Have suitable venous access for blood sampling.
  11. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

Volunteers will be excluded from the study if there is evidence of any of the following:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or significant neurological or psychiatric disease (including history of epilepsy or seizures), including any acute illness or major surgery within the past 3 months determined by the Investigator to be .
  2. Current infection that requires antibiotic, antifungal, antiparasitic or antiviral medications.
  3. Any history of malignant disease in the last 10 years (excludes completely treated cutaneous squamous cell or basal cell carcinoma).
  4. Presence of clinically relevant from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.
  5. Use of or having plans to use systemic immunosuppressive (e.g., , methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon, with the exception of topical steroid creams) during the study or within 3 months prior to the first study drug administration.
  6. Liver function test results (i.e., [AST], alanine aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and (total, conjugated and unconjugated) elevated more than 1.2-fold above the (ULN).
  7. Positive test results for active (HIV-1 and HIV-2), surface antigen (HBsAg) or virus (HCV) antibodies at the screening visit.
  8. Presence or having sequelae of gastrointestinal, liver (including Gilbert's syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  9. Estimated (CrCl) \< 80 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.
  10. Regular use of substance abuse or alcohol abuse within 3 months prior to Screening, where "regular" is defined as >21 units of alcohol per week for males and >14 units of alcohol per week for females. One unit is equivalent to 8 g of alcohol: a half-pint (\~285 mL) of beer, 1 glass (125 mL) of wine or 1 measure (25 mL) of spirits.
  11. Positive drug or alcohol test results at the screening visit or at check-in (Day -1) (may be repeated once, if a positive test was recorded in the first instance, at the discretion of the PI or designee).
  12. Use of any systemically absorbed prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 × half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 2000 mg per day of paracetamol and per local or national labelling) or hormonal .
  13. History of demonstrated clinically significant (required intervention, e.g., emergency room visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would increase the risk of having allergic reactions associated with product administration.
  14. Known to any of the study drug ingredients.
  15. Use of any vaccinations within 7 days prior to the first study drug administration, or plan to use any vaccinations within 2 weeks after the last dose.
  16. Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study drug administration.
  17. The healthy volunteer has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  18. Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
  19. Is an employee of an Investigator or Sponsor or an immediate relative of an investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    SR750 tablet

    Ascending single and multiple doses of SR750 tablets orally

    Drug: SR750 tablet

  • Placebo comparator
    matching placebo

    Ascending single and multiple doses of matching placebo orally

    Drug: matching placebo

Interventions

  • DrugSR750 tablet

    The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.

  • Drugmatching placebo

    The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.

06

What researchers measure

Primary outcomes

  1. The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR750

    AE: adverse event

    Time frame: Up to Day15 for the safety follow up since Day1

Other outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: Up to Day 10

  2. Tmax

    Time of peak plasma concentration

    Time frame: Up to Day 10

  3. Ctrough

    Trough concentrations, part B only.

    Time frame: Up to Day 10

  4. AUC0-t

    Area under the concentration-time curve from 0 to time of last quantifiable concentration

    Time frame: Up to Day 10

  5. AUC0-∞

    Area under the concentration-time curve from 0 to infinity

    Time frame: Up to Day 10

  6. t1/2

    Apparent terminal elimination half-life

    Time frame: Up to Day 10

  7. Ae

    Cumulative amount of unchanged drug excreted in urine

    Time frame: Up to Day 3, cohort 3 in part A only.

  8. CLr

    Renal clearance

    Time frame: Up to Day 3, cohort 3 in part A only.

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Oct 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 19, 2021
StartActual
Oct 29, 2021
Primary completionActual
Oct 14, 2022
CompletionActual
Oct 14, 2022
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05083468
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Oct 29, 2021
Primary completion
Oct 14, 2022
Completion
Oct 14, 2022
Last update
Nov 29, 2024

Study contacts

Cameron Johnson
study director · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion